Cellular distribution of injected PLGA-nanoparticles in the liver

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 5, 2016, Pages 1365-1374

  Park, Jin Kyu ^a,b   Utsumi, Teruo ^a   Seo, Young Eun ^c   Deng, Yang ^c   Satoh, Ayano ^d   Saltzman, William Mark ^c   Iwakiri, Yasuko ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kyungpook National University   (South Korea)

^c Yale University   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

Hepatic stellate cells; Hepatocytes; Kupffer cells; Liver sinusoidal endothelial cells; Nanomedicine

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CELLS; CYTOLOGY; LIPOSOMES; LIVER; MACROPHAGES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

CELL POPULATIONS; CELLULAR DISTRIBUTIONS; DRUG LOADED NANOPARTICLE; HEPATIC STELLATE CELLS; HEPATOCYTES; KUPFFER CELLS; LIVER SINUSOIDAL ENDOTHELIAL CELLS; PLGA NANOPARTICLES;

ENDOTHELIAL CELLS;

CLODRONIC ACID; DYE; LIPOSOME; NANOPARTICLE; POLYMER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLS BY BODY ANATOMY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; KUPFFER CELL; LIVER; LIVER CELL; LIVER PERFUSION; LIVER SINUSOID; MALE; MOUSE; NONHUMAN; STELLATE CELL; TARGET CELL; DRUG DELIVERY SYSTEM; HUMAN;

DRUG DELIVERY SYSTEMS; HEPATOCYTES; HUMANS; KUPFFER CELLS; LACTIC ACID; LIVER; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84962195837     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.01.013     Document Type: Article

References (40)

1. Cheng C.J., Tietjen G.T., Saucier-Sawyer J.K., Saltzman W.M. A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov 2015, 14:239-247.
2. Chen Y., Mohanraj V.J., Wang F., Benson H.A. Designing chitosan-dextran sulfate nanoparticles using charge ratios. AAPS PharmSciTech 2007, 8:E98.
3. Bergen J.M., von Recum H.A., Goodman T.T., Massey A.P., Pun S.H. Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 2006, 6:506-516.
4. Caruthers S.D., Wickline S.A., Lanza G.M. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007, 18:26-30.
5. Kang J.H., Toita R., Murata M. Liver cell-targeted delivery of therapeutic molecules. Crit Rev Biotechnol 2014, 1-12.
6. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002, 20:1668-1676.
7. Reddy L.H., Couvreur P. Nanotechnology for therapy and imaging of liver diseases. J Hepatol 2011, 55:1461-1466.
8. Fu S., Naing A., Moulder S.L., Culotta K.S., Madoff D.C., Ng C.S., et al. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther 2011, 10:1300-1307.
9. Li F.Q., Su H., Chen X., Qin X.J., Liu J.Y., Zhu Q.G., et al. Mannose 6-phosphate-modified bovine serum albumin nanoparticles for controlled and targeted delivery of sodium ferulate for treatment of hepatic fibrosis. J Pharm Pharmacol 2009, 61:1155-1161.
10. van Beuge M.M., Prakash J., Lacombe M., Gosens R., Post E., Reker-Smit C., et al. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther 2011, 337:628-635.
11. Yang N., Ye Z., Li F., Mahato R.I. HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells. Bioconjug Chem 2009, 20:213-221.
12. Adrian J.E., Poelstra K., Scherphof G.L., Molema G., Meijer D.K., Reker-Smit C., et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems. J Hepatol 2006, 44:560-567.
13. Beljaars L., Molema G., Weert B., Bonnema H., Olinga P., Groothuis G.M., et al. Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999, 29:1486-1493.
14. Bisht S., Khan M.A., Bekhit M., Bai H., Cornish T., Mizuma M., et al. A polymeric nanoparticle formulation of curcumin (NanoCurc) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Invest 2011, 91:1383-1395.
15. Giannitrapani L., Soresi M., Bondi M.L., Montalto G., Cervello M. Nanotechnology applications for the therapy of liver fibrosis. World J Gastroenterol 2014, 20:7242-7251.
16. Dong L., Zuo L., Xia S., Gao S., Zhang C., Chen J., et al. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis. J Gene Med 2009, 11:229-239.
17. Bhatia S.N., Underhill G.H., Zaret K.S., Fox I.J. Cell and tissue engineering for liver disease. Sci Transl Med 2014, 6:245sr2.
18. Iwakiri Y., Shah V., Rockey D.C. Vascular pathobiology in chronic liver disease and cirrhosis - Current status and future directions. J Hepatol 2014, 61(4):912-924.
19. Sadauskas E., Wallin H., Stoltenberg M., Vogel U., Doering P., Larsen A., et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 2007, 4:10.
20. Kermanizadeh A., Chauche C., Balharry D., Brown D.M., Kanase N., Boczkowski J., et al. The role of Kupffer cells in the hepatic response to silver nanoparticles. Nanotoxicology 2014, 8(Suppl. 1):149-154.
21. Chiannilkulchai N., Ammoury N., Caillou B., Devissaguet J.P., Couvreur P. Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother Pharmacol 1990, 26:122-126.
22. Wang W., Soroka C.J., Mennone A., Rahner C., Harry K., Pypaert M., et al. Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. Gastroenterology 2006, 131:878-884.
23. Tavoloni N. The intrahepatic biliary epithelium: an area of growing interest in hepatology. Semin Liver Dis 1987, 7:280-292.
24. Daoust R., Cantero A. The numerical proportions of cell types in rat liver during carcinogenesis by 4-dimethylaminoazobenzene (DAB). Cancer Res 1959, 19:757-762.
25. Wilczewska A.Z., Niemirowicz K., Markiewicz K.H., Car H. Nanoparticles as drug delivery systems. Pharmacol Rep 2012, 64:1020-1037.
26. Ramakrishna S., Kwaku Dad A.B., Beloor J., Gopalappa R., Lee S.K., Kim H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 2014, 24:1020-1027.
27. Jimenez Calvente C., Sehgal A., Popov Y., Kim Y.O., Zevallos V., Sahin U., et al. Specific hepatic delivery of procollagen alpha1(I) siRNA in lipid-like nanoparticles resolves liver fibrosis. Hepatology 2015, 62(4):1285-1297.
28. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008, 26:431-442.
29. Duong H.T., Dong Z., Su L., Boyer C., George J., Davis T.P., et al. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension. Small 2015, 11:2291-2304.
30. Blomhoff R., Green M.H., Green J.B., Berg T., Norum K.R. Vitamin A metabolism: new perspectives on absorption, transport, and storage. Physiol Rev 1991, 71:951-990.
31. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010, 2:14.
32. Rensen P.C., Sliedregt L.A., Ferns M., Kieviet E., van Rossenberg S.M., van Leeuwen S.H., et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem 2001, 276:37577-37584.
33. Bartneck M., Warzecha K.T., Tacke F. Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr 2014, 3:364-376.
34. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
35. Breunig M., Lungwitz U., Liebl R., Goepferich A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A 2007, 104:14454-14459.
36. Conwell C.C., Liu F., Huang L. Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther 2008, 16:370-377.
37. Khazanov E., Simberg D., Barenholz Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J Gene Med 2006, 8:998-1007.
38. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B: Biointerfaces 2010, 75:1-18.
39. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505-522.
40. Vert M., Mauduit J., Li S. Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials 1994, 15:1209-1213.